All eyes have been on the first selective COX-2 inhibitors, celecoxib (Pharmacia and Pfizer's Celebrex) and rofecoxib (Merck's Vioxx), for the...
Acute Ischemic Stroke is a new study from Decision Resources, Inc., that examines the significant unmet needs in the management of ischemic stroke...
The growing number of postmenopausal women worldwide translates into new challenges for clinicians as they strive to help women stay healthy during...
Parkinson's Disease is a new study from Decision Resources, Inc. that identifies areas of opportunity for companies competing in the Parkinson's...
Using Clinical Trials to Strategic Advantage is a new DR Report from Decision Resources, Inc., that explains how clinical trials can be invaluable...
Decision Resources, Inc., announces the publication of Emerging Delivery Systems for Biopharmaceuticals, a new DR Report that offers crucial...
Post-Myocardial Infarction is a new study from Decision Resources, Inc., that examines how the need for better and novel cardioprotective agents to...
Asthma is a new Decision Resources study that examines novel drug development efforts arising from a wealth of research into the pathophysiology of...